To characterize changes in immune cell composition after therapy, cellular expansion was quantified in blood and tumors (Fig. 4L): CTRL-not-α-mIL2 induced a strong expansion of peripheral blood NK cells, with more modest changes to intratumoral populations, whereas CD8-mIL2 demonstrated robust and selective CD8+ T-cell expansion, both in blood and at the tumor site (Fig. 4M). The gene discussed is CD8A; the disease is neoplasm.